Identification of a cyclic peptide inhibitor of platelet-derived growth factor–BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts  by Brennand, David M. et al.
FEBS Letters 413 (1997) 70-74 FEBS 19033 
Identification of a cyclic peptide inhibitor of platelet-derived growth 
factor-BB receptor-binding and mitogen-induced DNA synthesis in 
human fibroblasts 
David M. Brennand*, Ulla Dennehy, Vincent Ellis, Michael F. Scully, Poonam Tripathi, 
Vijay V. Kakkar, Geeta Patel 
Leopold Muller Laboratory, Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, Chelsea, London SW3 6LR, UK 
Received 27 June 1997 
Abstract Peptides corresponding to residues from Loops I and 
III of platelet-derived growth factor-BB (PDGF-BB) were 
examined for their potential to act as PDGF antagonists. We 
have identified two peptides which directly stimulated DNA 
synthesis in human dermal fibroblasts and a cyclic peptide which 
inhibited PDGF-induced DNA synthesis. The inhibitory action of 
cyclic PDGF-BB73 81, on DNA synthesis was shown to be 
restricted to cells which express PDGF receptors. Also cyclic 
PDGF-BB73 81 specifically competed for 125I-labelled PDGF-
BB but not for 125I-labelled EGF binding to their respective 
cellular receptors. The cyclic peptide therefore provides a 
minimum structure to investigate PDGF/receptor interactions 
and our findings confirm the importance of the loop configuration 
of PDGF-BB73 81 in the native molecule. The cyclic peptide may 
constitute a basis for developing more potent inhibitors of PDGF 
action. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Platelet-derived growth factor (PDGF) is a major mitogen 
and chemotactic factor in connective tissues [1,2]. These prop-
erties provide PDGF with important roles in: wound healing, 
development of atherosclerotic lesions, restenosis of arteries 
after angioplasty [1,3], tumorigenesis [4,5], glomerulonephritis 
[6] and rheumatoid arthritis [7]. 
The three PDGF isoforms, homo- or heterodimers of re-
lated A and B polypeptides exert their biological effects 
through binding to a and [5 cell surface receptor subunits 
causing their dimerisation to homo- and heterodimers. Sub-
sequent receptor trans-autophosphorylation leads to activa-
tion of the intrinsic tyrosine kinase activity (see [8] for review). 
PDGF-A and -B chains have 60% amino acid identity with 
full conservation of 8 cysteine residues [9], but whilst PDGF-
BB binds to both a- and |3-receptors with different affinities, 
the PDGF-A chain binds only to the oc-receptor with a high 
affinity [8]. 
The X-ray crystal structure of the homodimer of human 
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PDGF-BB shows that loops I and III are extremely flexible, 
exposed to solvent and held in close proximity to each other 
possibly through hydrophobic interactions between Arg27 and 
Leu38 at the ends of loop I, and Arg73, lie70, He77, Pro82 and 
Phe84 at the periphery of loop III [10]. Site-directed mutagen-
esis studies have revealed the importance of PDGF-BB resi-
dues Arg28, Leu29, Asn34, Asn36, Phe37, Leu38 (Loop I) and 
Arg73, He77, Lys80 (Loop III) in receptor binding [11-15]. 
Antagonists of PDGF receptor interactions would be ex-
pected to block or retard lesion formation and might be clin-
ically beneficial in chronic inflammatory conditions as well as 
in atherosclerosis. Anti-PDGF antibodies have been shown to 
inhibit the binding and mitogenic effects of PDGF on murine 
embryo fibroblasts [16], to inhibit the chemotactic effect of 
PDGF on pulmonary artery fibroblasts [17] and to inhibit 
intimal lesion development after de-endothelialisation of the 
carotid arteries of rats [18]. Further inhibitors of PDGF-in-
duced mitogenesis include Trapidil [19], 2-bromomethyl-5-
chlorobenzene sulfonylphthalimide [20] and Suramin [21], 
although all suffer a lack of specificity. A 13-amino-acid pep-
tide ANFLVWEIVRKKP which combines PDGF-BB35-40 
(loop I) and PDGF-BB76"82 (loop III) containing a trypto-
phan residue modified with thianisole has also been identified 
as a possible antagonist [22]. 
We have examined the agonist/antagonist properties of a 
series of peptides corresponding to residues in loops I and 
III of PDGF-BB using human dermal fibroblasts. We have 
identified two peptides which are relatively potent in stimulat-
ing DNA synthesis and a cyclic peptide derived from these 
which inhibits PDGF-induced DNA synthesis. We demon-
strate specificity of the cyclic peptide in terms of inhibition 
of growth factor binding and show a correlation of its ability 
to inhibit cellular proliferation with the presence of PDGF 
receptors on cells. 
2. Materials and methods 
2.1. Materials 
All chemicals were of the highest grade and were from Sigma 
Chemical Company Ltd., Poole, UK, unless otherwise stated. All 
reagents for peptide synthesis were from PerSeptive Biosystems, Hert-
ford, UK. Myoclone fetal bovine serum (FBS), Dulbecco's modified 
Eagles medium (DMEM), medium Ml99, L-glutamine, sodium pyru-
vate and gentamicin were from Life Technologies Ltd., Paisley, Scot-
land. Tissue culture plastics (Falcon plastics) were from Marathon 
Laboratory Supplies, London, UK. Methyl-[3H]-thymidine (1.85 
TBq/mmol) was from ICN Biomedicals Ltd., Thame, UK. Recombi-
nant human PDGF-BB, EGF and FGF (146-amino-acid isoform) 
were from R&D Systems Europe Ltd., Abingdon, UK. 125I-Labelled 
recombinant human growth factors were from Amersham Interna-
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tional pic, Amersham, UK. The cell lines HFFF2 (human dermal 
foreskin fibroblast), A431 (squamous carcinoma) and COS-1 (trans-
formed African green monkey kidney) were obtained from the Euro-
pean Tissue Culture Collection, Porton Down, UK. 
2.2. General methods for peptide synthesis 
Peptides were synthesised by continuous-flow solid-phase synthesis 
using the Fmoc strategy [23]. N-terminal blocking was performed 
using 45% acetic anhydride in 7V,Af-dimefhyl-formamide for 30 min 
prior to cleavage and deprotection. Cyclisation of peptides was carried 
out on line using allyl based protection of Glu. Following removal 
of the Na-Fmoc group, head to tail cyclisation was performed 
using 0-(7-azabenzotriazol-1 -yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate and l-hydroxy-7-azabenzotrizole as per manufactur-
er's instructions. Peptides were purified by reverse-phase HPLC on a 
Vydac C18 column (22x250 mm) using a 30 min gradient of 10-60% 
acetonitrile in 0.1% trifluoroacetic acid. Identification and character-
isation of the purified peptides were performed using analytical re-
verse-phase HPLC and ESI mass-spectrometry. Peptide sequences and 
defined peptide numbers are given in Table 1. 
2.3. Cell culture 
Complete DMEM and complete Ml99 are defined as the respective 
medium supplemented with 4 mM L-glutamine, 100 IU/ml penicillin 
and 100 ug/ml streptomycin. HFFF2 (passage numbers 11-15) and 
COS-1 cells were maintained in complete DMEM containing 10% 
FBS, at 37°C in a humidified chamber containing 10% CO2, and 
5% C0 2 , respectively. A431 were maintained in complete Ml99 con-
taining 10% FBS under 5% CO2. Cells were kept in a subconfluent 
condition and were passaged following mild trypsinisation every 3^1 
days into 75 cm2 flasks. 
2.4. Effects of peptides on DNA synthesis 
HFFF2 cells were seeded into 48-well flat-bottom tissue culture 
plates at a cell density of 8000 cells/well, and grown until approxi-
mately 50% confluent (15000 cells/well, 2 days). Cells were rendered 
quiescent by replacing the medium with complete DMEM containing 
0.2% or 0.5% FBS, for 64-72 h. The agonist behaviour of the peptides 
was studied by replacing the medium, at time zero, with complete 
DMEM containing 0.5% FBS and varying concentrations of the dif-
ferent peptides listed in Table 1. The antagonist effects were examined 
by coaddition of peptides with PDGF (15 ng/ml, 0.5 nM) in complete 
medium containing 0.2% FBS. In one set of experiments the medium 
was replaced after 4 h with complete DMEM containing 0.2% FBS. 
Each concentration was performed in triplicate, and experiments re-
peated at least twice. [3H]Thymidine (11.1 Kbq/well) was added at 
time 22 h and incubated until time 28 h. Medium was aspirated, cells 
were washed twice with cold PBS (magnesium and calcium free), fixed 
by the addition of ice-cold 10% TCA (30 min), and washed with cold 
70% ethanol. Following solubilisation of cells in 0.1 N NaOH 
(30 min), incorporated [3H]thymidine was quantified by scintillation 
counting. Inhibition of cellular proliferation was calculated as % re-
duction in [3H]thymidine incorporation with respect to the stimulation 
achieved in the absence of peptide. 
2.5. Receptor-binding inhibition assay 
The general methodology of Bowen-Pope and Ross [24] was fol-
lowed. Briefly, 24-well flat-bottomed tissue culture plates were seeded 
with human fibroblasts, 25000 cells per well in DMEM containing 
10% FBS, and cultured until confluent (2 days). The medium was 
replaced with DMEM containing 0.2% FBS for a period of 24 h. 
Wells were washed once with PBS and incubated for 10 min at 4°C 
with 500 |ll of binding buffer (PBS/20 mM HEPES, pH 7.4 containing 
5% BSA). Varying concentrations of peptide plus 125I-labelled PDGF 
(0.202 nM, 22.94 Tbq/mmol) or 125I-labelled EGF (0.09 nM, 
51.54 TBq/mmol) in binding buffer were added to the cells in a total 
volume of 300 nl/well, and incubated for 2 h at 4°C on an orbital 
shaker. Wells were washed 3 times with cold binding buffer, and then 
cells were solubilised by incubation with 500 ul of PBS containing 1% 
(w/v) Triton X-100 and 1% (w/v) BSA for 1 h prior to determination 
of radioactivity using a gamma counter. For controls, wells were in-
cubated with an additional amount of cold PDGF-BB or EGF 
(200 molar excess over labeled growth factor). 
3. Results and discussion 
Functional activity of protein molecules is often linked to 
dynamic conformational variations [25,26]. This may explain 
why loops I and III of P D G F are found to be very highly 
flexible with associated high temperature coefficients found in 
the X-ray crystal structure [10]. Peptides corresponding to 
these regions of P D G F which had previously been shown to 
be crucial for receptor binding were chosen for this study [11 -
15]. Recognition by receptors of flexible linear oligopeptides is 
sensitive to the entropic penalty incurred when the peptide 
becomes constrained to a well-defined region of its conforma-
tional space upon receptor binding [27,28]. W e therefore rea-
soned that cyclisation of the peptides would enable them to 
mimic their natural conformations within P D G F - B B , and 
would be predicted to provide improved binding affinity to 
the P D G F receptors, as compared to their linear counterparts. 
The series of peptides corresponding to P D G F - B B 7 3 - 8 1 in-
clude combinations where end-terminal charge groups have 
been modified by either acetylation of the N-terminus or ami-
dation of the C-terminus, or Cys included at the C-terminus 
to allow peptide dimerisation. In the design of P8 , 3 Gly were 
included in the sequence. These form a pliant linker which is 
estimated to be able to bridge the distance of 91.3 nm between 
He25 and Leu3 8, as defined by the crystal structure [10], and 
also maintain the flexibility of this loop I peptide. 
Peptides were initially tested for their effects on growth-
arrested human fibroblasts. P I , P2 , P 3 , P 5 , and P 8 induced 
a direct stimulatory effect on these cells, but only at a con-
centration of 100 \xM (Fig. 1). P 4 and P 6 induced cellular 
proliferation even lower than 6.25 u M this correlated with 
the presence of Cys in both peptides and the lack of N-termi-
nal acetylation. The presence of Cys in both these peptides 
and subsequent thiol cross-linking thus allows them to cause 
P D G F receptor dimerisation, a factor which is crucial for the 
normal PDGF-induced mitogenic response [8]. The cyclic loop 
III construct, P7 , showed no stimulatory effect, but reduced 
D N A synthesis below that observed with the growth-arrest 
Table 1 
Peptides used in this work 
Peptide number Sequence and corresponding residue numbers 
1 7 3RKIEIVRKK8 1 
2 Ac - 7 3 RKIEIVRKK 8 1 
3 Ac - 7 3 RKIEIVRKK 8 1 -NH 2 
4 7 3 RKIEIVRKK 8 1 -C 
5 A c - 7 3 R K I E I V R K K 8 1 - C 
6 7 7 I V R K K 8 1 - C - 7 3 R K I E 7 6 
7 7 7 I V R K K 8 1 - C - 7 3 R K I E 7 6 
G G - 2 5 I (S)RRLIDRTNANFL3 8-CG 
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Fig. 1. The ability of peptides to directly induce DNA synthesis in growth-arrested human fibroblasts. Peptides in growth-arrest medium were 
incubated with cells at varying concentrations and the [3H]thymidine uptake measured as described in Section 2. Comparison is made to con-
trols grown in the absence (A), and presence (B) of PDGF-BB (0.5 nM). Results represent means ± SEM (« = 3). 
control, throughout the range of peptide concentrations 
tested. 
The Kd for the interaction of PDGF-BB with purified 
PDGF extracellular receptor domains and with cells having 
very low copy numbers of receptor is approximately 1 nM 
[29,30]. By contrast on cells expressing the receptor in high 
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Fig. 3. The ability of peptides to inhibit PDGF-induced DNA synthesis in growth-arrested human fibroblasts. Co-incubation of PDGF with 
varying concentrations of peptides was either for 4 or 28 h (indicated on the x axis), as described in Section 2. % Inhibition of [3H]thymidine 
incorporation is calculated with respect to the uptake measured in the absence of peptide. Results represent means ± SEM (n = 3). 
copy numbers, i.e. NIH 3T3 and human foreskin fibroblasts, 
the Kd of the interaction is approximately 10 pM. This high 
affinity is presumed to be due to the simultaneous binding of 
the PDGF dimer to two receptors, as these cells have about 
20000-30000 a-receptors and 100000 (3-receptors/cell [31]. 
We investigated the ability of loop III peptides P2, P4, P5, 
P6, and P7 to inhibit the binding of 125I-labelled PDGF-BB to 
human dermal fibroblasts. Only peptide P7 was able to inhibit 
this binding which was achieved with an EC50 of 220 uM (Fig. 
2, other data not shown). This ability to inhibit growth factor 
binding proved to be specific as peptide P7 was unable to 
inhibit the binding of 125I-labelled EGF, which has a reported 
K<\ of 0.33-0.39 nM for binding to its full-length receptors 
[32]. This increase in the binding affinity of the cyclic peptide 
(P7) as compared to its linear counterparts is in agreement 
with our original hypothesis. The 67% sequence homology of 
PDGF-BB73-81 with the corresponding 9-amino-acid loop III 
region PDGF-AA allows for the possibility that the peptides 
will also mimic PDGF-AA loop III, and this has yet to be 
examined. 
An investigation into the ability of each peptide to affect 
PDGF-induced DNA synthesis (4 h co-incubation) of human 
fibroblasts showed that a reduction of 10-30% was induced by 
peptides P3, P6, and P8 (Fig. 3). In the presence of a rela-
tively high concentration of PDGF-BB (0.5 nM) only P7 
proved to be a very strong inhibitor of PDGF-BB-induced 
[3H]thymidine incorporation, with an EC50 of 9.5 uM. The 
other peptides (Table 1) were without effect. The reason for 
P7 having a 30-fold greater EC50 for inhibition of PDGF-BB 
binding as compared to the EC50 for its inhibition of DNA 
synthesis is as yet unexplained, but may reflect the differences 
in inhibition of the biological effects of PDGF-BB versus total 
receptor occupancy. The greater affinity of PDGF-BB, as 
compared to P7, for the PDGF-receptor can be explained 
by the binding cooperativity provided by loops I and II 
present in PDGF-BB. 
Other studies showed that a 28 h co-incubation of cells with 
PDGF-BB and anti-PDGF-BB antibodies provides a more 
rigorous test of the inhibition of mitogen-induced cellular pro-
liferation than a shorter 4 h co-incubation (unpublished data). 
When PDGF and each of the peptides were incubated with 
cells during a 28 h period of growth it was observed that 
inhibition of PDGF-induced thymidine uptake by peptide 
P7 still occurred, with an EC50 of 6.3 uM (Fig. 3). Peptide 
P7, when incubated at 100 uM with cells not expressing 
PDGF receptors for 28 h (A431 or COS-1, [33,34]), had no 
effect upon DNA synthesis. 
In summary, from a series of peptides from loops I and III 
of PDGF-BB we have identified two peptides which are able 
to stimulate cellular proliferation at a concentration of less 
than 6.2 uM. These peptides were not, however, able to in-
hibit the high-affinity interaction of 125I-labelled PDGF-BB 
binding to its receptor. A further peptide P7 was identified 
which inhibited PDGF-BB-induced mitogenesis, specifically 
inhibited 125I-labelled PDGF-BB binding to its cellular recep-
tors, and whose action was restricted to cells expressing 
PDGF receptors. Peptide antagonists of PDGF may be useful 
clinically in chronic inflammatory conditions and in prevent-
ing restenosis post-angioplasty and peptide P7 may form a 
useful initial design step from which further compounds 
with increased potency can be developed. The mechanistic 
basis for the inhibition of PDGF activity by peptide P7 is 
currently under investigation. 
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